Tokyo, May 4 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061446) titled 'Development of patient registry and biorepository to establishment of standard therapy for histiocytosis' on May 4.
Study Type:
Observational
Primary Sponsor:
Institute - The Institute of Medical Science Research Hospital, The University of Tokyo
Condition:
Condition - histiocytosis
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - This study aims to systematically collect clinical information on histiocytosis, including presentation, diagnosis, treatment, and outcomes, to clarify the real-world disease characteristics and improve clinical practice. In addition, biological specimens such as tissue, blood, and bone marrow will be stored to support future genetic analyses and centralized pathological review.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1) Patients diagnosed with histiocytosis based on pathological examination, including suspected cases.
All age groups, all histiocytic disorders, with no restriction on the date of diagnosis.
Patients who have been cured or who are deceased are also eligible.
2) Patients who have provided written informed consent to participate in the study
Key exclusion criteria - Patients who are judged by the investigators to be inappropriate for inclusion in the study.
Target Size - 300
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2025 Year 02 Month 24 Day
Date of IRB - 2025 Year 03 Month 24 Day
Anticipated trial start date - 2025 Year 04 Month 01 Day
Last follow-up date - 2030 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070198
Disclaimer: Curated by HT Syndication.
